Self-expanding TAVR system shows durable benefits in low-risk patients at 3 years

NEW ORLEANS — At 3 years, patients with severe aortic stenosis at low surgical risk who had transcatheter aortic valve replacement with a self-expanding valve continued to have lower risk for death or stroke than those who had surgical AVR. In the main results of the Evolut Low Risk Trial, risk for all-cause mortality or disabling stroke at 2 years was numerically lower and noninferior in

Related Keywords

Johnk Forrest ,Katie Kalvaitis ,Byerik Swain ,Edwards Lifesciences ,Amye Simone ,American College Of Cardiology Scientific Session ,Journal Of The American College Cardiology ,Yale University School Of Medicine ,Medtronic ,Yale New Haven Health System ,American College ,New England Journal ,Medicine Late Breaking Clinical ,Cardiology Scientific Session ,New Orleans ,Evolut Low Risk Trial ,Yale University School ,Cardiology Scientific ,